Main Article Content
Abstract
Background: Triple-negative breast cancer (TNBC) is an aggressive molecular subtype that lacks oestrogen, progesterone and human epidermal growth factor receptor 2 (HER2) receptors and retains cytotoxic chemotherapy as its principal systemic option, creating a rationale for adjunctive phytotherapy. Annona muricata L. (Annonaceae), known in Indonesia as sirsak, contains Annonaceous acetogenins with well-documented mitochondrial and apoptotic activity.
Objective: This study integrated molecular docking with in vitro pharmacology to characterise the anticancer effects of a high-performance liquid chromatography (HPLC)-standardised acetogenin-enriched fraction (AEF) from Indonesian A. muricata leaves on TNBC cells.
Methods: Annonacin, bullatacin, squamocin and muricatacin were docked against epidermal growth factor receptor (EGFR), B-cell lymphoma 2 (Bcl-2), cyclin-dependent kinase 2 (CDK2), caspase-3 and topoisomerase II-α (AutoDock Vina); AEF was tested on MDA-MB-231 and MDA-MB-468 TNBC cells with MCF-10A non-tumorigenic controls (n = 6 independent biological replicates per arm). Outcomes included viability (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MTT), apoptosis (Annexin-V/propidium iodide, PI), cell-cycle distribution (PI), caspase-3/7 luminescence, Western blotting (Bcl-2, Bax, cleaved caspase-3, cyclin D1 and p21) and mitochondrial transmembrane potential (ΔΨm)/reactive oxygen species (ROS).
Results: Bullatacin showed the strongest binding to Bcl-2 (ΔG = −9.6 kcal/mol) and caspase-3 (ΔG = −8.9 kcal/mol). AEF inhibited MDA-MB-231 viability with an IC50 of 12.4 µg/mL (95% confidence interval [CI] 10.8–14.1) and yielded a selectivity index of 4.20 over MCF-10A. Apoptotic cells increased 4.62-fold, the G1 fraction rose from 41.2% to 64.8% (p < 0.001), caspase-3/7 activity rose 3.81-fold and the Bcl-2/Bax ratio decreased by 61%.
Conclusion: Bullatacin-rich Annona muricata acetogenins selectively induce intrinsic apoptosis and G1 arrest in TNBC cells, supporting their further translational development as Indonesian phytotherapeutic leads for hormone-refractory breast cancer.
Keywords
Article Details
Authors retain copyright and grant Eureka Herba Indonesia the non-exclusive right of first publication. Unless otherwise stated, articles are published under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0). Authors may share and archive their work with proper acknowledgement of initial publication, DOI, and license.
